Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
Cathie Wood's ARK Sells CareDx, Buys Recursion Pharmaceuticals Stock
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position
Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns
Express News | Recursion Pharmaceuticals Shares Rise 2% Premarket After Sliding to Over Nine-Month Lows on Tue
Express News | Jefferies Maintains Hold on Recursion Pharmaceuticals, Lowers Price Target to $6
Recursion Pharmaceuticals Analyst Ratings
Express News | Recursion Pharmaceuticals Shares Are Trading Lower. The Company Announced Top-line Results of the SYCAMORE Trial for REC-994 in Symptomatic CCM Patients
Express News | Recursion Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $8 From $9
Trending Industry Today: Recursion Pharmaceuticals Leads Losses In NVIDIA Portfolio Stocks
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Express News | Recursion Pharmaceuticals Falls 10% Premarket; Co Says Blood Vessel Disorder Drug Meets Main Goal in Mid-Stage Study
Express News | Recursion Pharmaceuticals Inc - Meeting With FDA Anticipated to Discuss Additional Clinical Study
Express News | Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (Ccm), Has Met Its Primary Endpoint of Safety and Tolerability
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), Has Met Its Primary Endpoint of Safety and Tolerability
Recursion Pharmaceuticals (RXRX) Gets a Hold From Morgan Stanley
Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals